Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain
MEXICO CITY, May 6, 2025 /CNW/ - Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", 6838.TW), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery, upon regulatory approval.
Apotex Inc. Logo (CNW Group/Apotex Inc.)
APP13007 was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the corticosteroid clobetasol propionate, and it is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. This novel formulation proved statistically and clinically superior to its matching placebo in Phase 3 trials in the United States (p<0.001).
This license agreement for the Mexican market adds to Apotex's existing exclusive rights to this product in Canada.
"At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy," said Alok Kanti, President, Apotex International.
"Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include the Mexico territory," said Erick Co, President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as soon as possible."
About Apotex Inc.
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US-Mexico steel imports, Palantir stock, DoorDash & Symbiosys
Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including steel manufacturer Cleveland-Cliffs' (CLF) stock response to reports of US-Mexico trade talks, Palantir Technologies' (PLTR) move higher to a record intraday high, and DoorDash (DASH) acquiring advertising technology platform Symbiosys. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's Market Minute. Stocks looking for momentum here as investors digest softer than expected inflation data. Shares of steel manufacturer Cleveland-Cliffs sliding as the U.S. and Mexico may be nearing a deal. The two nations reportedly close to an agreement that would remove President Trump's 50% tariffs on steel imports up to a certain volume. That's according to Bloomberg. Palantir on the rise as shares eye a record high close. That stock already hitting record intraday highs as Mizuho lifts its price target on that name from 94 to 116. The firm citing Palantir's, quote, stronger momentum in net new commercial logos. And DoorDash announcing its acquisition of ad tech platform Symbiosis. The food delivery company looking to expand its off-site advertising capabilities. DoorDash also introducing a new suite of AI-powered tools. And that's your Yahoo! Finance Market Minute. For more on what's trending on Yahoo! Finance, scan the QR code below to track the best and worst performing stocks. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
New York Post
an hour ago
- New York Post
Bessent reveals whether Trump will extend tariff deadlines for other countries after breakthrough with China
The Trump administration is 'highly likely' to extend next month's deadline for countries to agree one-for-one trade deals — so long as they are engaged in 'good-faith negotiations,' Treasury Secretary Scott Bessent told lawmakers Wednesday. With a July 8 deadline looming for dozens of nations to strike lightning-quick agreements with the White House, Rep. Don Beyer (D-Va.) pressed Bessent about whether more time will be given. 'I would say, as I have repeatedly said, that there are 18 important trading partners,' Bessent told the tax-writing House Ways and Means Committee. 'It is highly likely that [with] those countries … or trading blocs in the case of the EU, who are negotiating in good faith, we will roll the day forward to continue good faith negotiations. If someone is not negotiating, then we will not.' Advertisement On April 2, which Trump dubbed 'Liberation Day,' he unveiled a 10% baseline tariff on virtually all imports flowing into the US and a myriad of customized rates on almost every country. 3 Treasury Secretary Scott Bessent hinted that an extension of the 'Liberation Day' tariff deadline is coming. AP 3 President Trump hasn't said whether he will extend his tariff deadlines. REUTERS Advertisement Seven days alter, Trump announced a 90-day pause on those customized rates to give time to negotiate deals. The White House has since claimed that last week was the deadline for countries to furnish their best offers on trade. Trump has also imposed a few other key trade deadlines, agreeing last month to delay a 50% planned tariff against the European Union until July 9 after it was set to take effect June 1. The administration has also reached an understanding on trade with the United Kingdom and earlier Wednesday, Trump confirmed progress with China on a 'deal' for a trade negotiation framework. Advertisement Should Trump and Chinese leader Xi Jinping approve the agreement, it will revive key elements of a trade truce with Beijing brokered in Geneva last month. That framework was intended to give the two economic giants until Aug. 10 to cut a more comprehensive trade arrangement. The Geneva arrangement saw China lower its tariffs on most US goods to 10% from 125%, and the US lower its duties down from as high as 145% after the two sides penalized each other in the aftermath of 'Liberation Day.' 3 President Trump quickly paused his 'Liberation Day' tariffs to allow time for negotiations. Advertisement Under the latest arrangement, China will face up to 55% tariffs on most exports, according to Trump. In addition to the 10% baseline rate and the tariffs on China, Trump has imposed a 25% rate on imports from Canada and Mexico that aren't subject to the US-Mexico-Canada Agreement, a 25% duty on foreign steel and aluminum imports, and another 25% levy on most foreign-made vehicles.
Yahoo
an hour ago
- Yahoo
GM's $4B Bet: Why Trump's Tariffs Just Rewired U.S. Auto Manufacturing
General Motors (NYSE:GM) is pulling a hard left on its decades-long offshore strategy. The automaker just unveiled a $4 billion investment plan to boost U.S. production over the next two yearsreshuffling factory lines in Michigan, Kansas, and Tennessee. Why now? Trump's tariffs. After years of defending its Mexico-heavy footprint, GM is betting that protectionist trade policies aren't going away. CFO Paul Jacobson told investors the changes will raise U.S. vehicle output by 300,000 units a year, with pickups like the Chevrolet Silverado and GMC Sierra coming back stateside. That shift alone could reduce GM's estimated $5 billion tariff exposureone reason shares popped 2.4% at 12.54pm after the news. Warning! GuruFocus has detected 2 Warning Sign with GM. It's a rare reversal. For decades, GM offshored to cut costs and sidestep ballooning retiree liabilities. But now, political risk has become just as costly. CEO Mary Barra, once criticized by Trump for closing an Ohio plant, has recalibrated. After several meetings with the president, Barra appears convinced: Mexican-made cars may face long-term penalties. The new plan brings production of the Equinox SUV to Kansas by 2027, along with the revamped Chevy Bolt EV. Meanwhile, Tennessee will assemble gas-powered Chevy Blazers, and Michigan's Orion plantoriginally meant for electric pickupswill shift gears to build gasoline versions starting 2027. The pivot isn't just logisticalit's strategic. By adding 3,000 to 4,000 U.S. jobs, GM could quiet critics and hedge political risk ahead of another turbulent election cycle. The company still plans to make some vehicles in Mexico, just at lower volumes. But the message is clear: GM is building againat home. With EV demand cooling and tariffs heating up, this could be the kind of long-game play investors shouldn't ignore. This article first appeared on GuruFocus. Sign in to access your portfolio
